Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New weekly shot aims to tame type 2 diabetes

NCT ID NCT07668388

Disease control Sponsor: Novo Nordisk A/S Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Sep 11, 2026 · Updated 6 times

Summary

This study tests a new medicine called UBT251, given as a weekly shot, in 300 adults with type 2 diabetes. Some participants will get UBT251, others will get a placebo or an existing drug (semaglutide). The goal is to see if UBT251 can safely lower blood sugar and help with weight loss.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
UBT251 (a weekly injection for type 2 diabetes)
What this could lead to
If successful, UBT251 could offer a new once-weekly option to help control blood sugar and possibly reduce weight in people with type 2 diabetes.
What could go wrong
This is an early Phase 2 dose-finding study, so it is not yet proven effective or safe. Side effects are unknown, and results may not lead to a better treatment than existing options like semaglutide.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 300 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2026

Expected to finish

Nov 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Male or female (sex assigned at birth, inclusive of all gender identities). * Age 18-75 years (both inclusive) at the time of signing the informed consent. * Diagnosed with type 2 diabetes greater than or equal to (≥) 180 days before screening. * Stable daily dose(s) ≥ 90 days before screening of the following antidiabetic drug(s) or combination regimen(s) at effective or maximum tolerated dose as judged by the investigator: metformin with or without sodium-glucose cotransporter-2 (SGLT2) inhibitor. * HbA1c of 7.0-10.5 percent (%) (53-91 millimoles per mole (mmol/mol)) (both inclusive) as assessed by central laboratory at screening. * Body mass index between 25.0 kg/m\^2 and 50.0 kg/m\^2 (both inclusive) at screening. Exclusion Criteria: * Treatment with any medication (prescription or over-the counter) or alternative remedies for the indication of diabetes or obesity other than stated in the inclusion criteria within 90 days before screening. However, short term insulin treatment for a maximum of 14 consecutive days and prior insulin treatment for gestational diabetes are allowed. * Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Verified by an eye examination performed within 90 days before screening or in the period between screening and randomisation. Pharmacological pupil-dilation is a requirement unless using a digital fundus photography camera specified for non-dilated examination. * Known hypoglycaemic unawareness as indicated by the investigator according to Clarke's questionnaire, question 8.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Diabetes mellitus type 2 are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

diabetes mellitus type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Diabetes mellitus type 2

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    70 sites in 9 countries. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • 1 Wojskowy Szpital Kliniczny z Poliklinika SPZOZ

    NOT_YET_RECRUITING

    Lublin, Lublin Voivodeship, 20-049, Poland

  • ARETEUS s.r.o.

    RECRUITING

    Trebišov, 075 01, Slovakia

  • Ark Clinical Research

    RECRUITING

    Fountain Valley, California, 92708, United States

  • Ark Clinical Research

    RECRUITING

    Long Beach, California, 90815, United States

  • Asan Medical Center_Endocrinology

    NOT_YET_RECRUITING

    Seoul, 05505, South Korea

  • Baker Heart and Diabetes Institute

    RECRUITING

    Melbourne, Victoria, 3004, Australia

  • CRS Clinical Research Services Mannheim GmbH (hVIVO Mannheim)

    RECRUITING

    Mannheim, 68167, Germany

  • Castle Hill Medical Centre

    RECRUITING

    Castle Hill, New South Wales, 2154, Australia

  • Catalina Research Institute, LLC

    RECRUITING

    Montclair, California, 91763, United States

  • Chosun University Hospital_Endocrinology

    NOT_YET_RECRUITING

    Gwangju, 61453, South Korea

  • Chrysalis Clinical Research

    RECRUITING

    St. George, Utah, 84790, United States

  • Clinica Korall S.R.L. Satu Mare

    RECRUITING

    Satu Mare, 440055, Romania

  • Clinical Best Solutions Sp. z o.o., Sp. k

    NOT_YET_RECRUITING

    Lublin, 20-011, Poland

  • Consano Clin Res-Shavano Park

    RECRUITING

    Shavano Park, Texas, 78231, United States

  • Cotton O'Neil Diabetes & Endocrinology

    RECRUITING

    Topeka, Kansas, 66606, United States

  • DSP Bochum, Diabetes- und Stoffwechselpraxis

    NOT_YET_RECRUITING

    Bochum, 44869, Germany

  • Eap Osona Sud Alt Congost S.L.P

    RECRUITING

    Centelles (Barcelona), 08540, Spain

  • Encore Medical Research LLC

    RECRUITING

    Hollywood, Florida, 33024, United States

  • Encore Medical Research of Weston

    RECRUITING

    Weston, Florida, 33331, United States

  • Equip D'assistencia Primaria Vic S.L.P.

    RECRUITING

    Vic, Barcelona, 08500, Spain

  • Flourish Research

    RECRUITING

    Birmingham, Alabama, 35205, United States

  • Formed 2 Sp. z o.o.

    RECRUITING

    Oświęcim, 32-600, Poland

  • H. Infanta Luisa_Endocrino y Obesidad

    RECRUITING

    Seville, 41010, Spain

  • H. Univ. Marqués de Valdecilla_Endocrinología

    NOT_YET_RECRUITING

    Santander, 39008, Spain

  • Herz- und Diabeteszentrum NRW - Bad Oeynhausen

    RECRUITING

    Bad Oeynhausen, 32545, Germany

  • Hospital Universitario de la Princesa

    RECRUITING

    Madrid, 28006, Spain

  • Hospital Vall d'Hebron

    RECRUITING

    Barcelona, 08035, Spain

  • Hunter Medical Research Institute - Endocrinology and Diabetes

    NOT_YET_RECRUITING

    New Lambton Heights, New South Wales, 2305, Australia

  • IMA Clinical Research

    RECRUITING

    Austin, Texas, 78745, United States

  • IN-DIA s.r.o.

    RECRUITING

    Lučenec, 984 01, Slovakia

  • InnoDiab Forschung GmbH

    RECRUITING

    Essen, 45136, Germany

  • KDCILM, LLC & Accellacare US, Inc.

    RECRUITING

    Wilmington, North Carolina, 28401, United States

  • Korea University Guro Hospital_Endocrinology

    NOT_YET_RECRUITING

    Seoul, 08308, South Korea

  • LifeDoc Health

    RECRUITING

    Memphis, Tennessee, 38115, United States

  • Los Angeles Institute for Metabolic Research

    RECRUITING

    Los Angeles, California, 90015, United States

  • MD Medical Research

    RECRUITING

    Oxon Hill, Maryland, 20745, United States

  • MEDI-DIA s.r.o.

    RECRUITING

    Sabinov, 08301, Slovakia

  • MEDISPEKTRUM s.r.o.

    RECRUITING

    Bratislava, 851 01, Slovakia

  • Mariodiab Clinic SRL

    RECRUITING

    Brasov, 500101, Romania

  • Medizinisches Versorgungszentrum Am Bahnhof Spandau GbR

    RECRUITING

    Berlin, 13597, Germany

  • Mesut Durmaz, Hof

    RECRUITING

    Hof, 95030, Germany

  • Midwest Inst For Clin Res

    NOT_YET_RECRUITING

    Indianapolis, Indiana, 46260, United States

  • Monroe Biomedical Research, LLC

    RECRUITING

    North Charleston, South Carolina, 29406, United States

  • NZOZ Vita-Diabetica Malgorzata Buraczyk

    RECRUITING

    Bialystok, Podlaskie Voivodeship, 15-879, Poland

  • Novatrials

    NOT_YET_RECRUITING

    Charlestown, New South Wales, 2290, Australia

  • PVN Kutató Kft.

    RECRUITING

    Budapest, 1102, Hungary

  • PharmQuest

    NOT_YET_RECRUITING

    Greensboro, North Carolina, 27408, United States

  • Plains Clinical Research Center, LLC_Fargo

    NOT_YET_RECRUITING

    Fargo, North Dakota, 58104, United States

  • Preferred Primary Care Physicians, Inc.

    RECRUITING

    Uniontown, Pennsylvania, 15401, United States

  • Private Practice - Dr. Laila A. Hassan

    RECRUITING

    Houston, Texas, 77089, United States

  • Pécsi Tudományegyetem ÁOK

    NOT_YET_RECRUITING

    Pécs, 7624, Hungary

  • Quality Research Inc

    RECRUITING

    San Antonio, Texas, 78209, United States

  • Radiance Clinical Research

    RECRUITING

    Lampasas, Texas, 76550, United States

  • Roger Chih Yu Chen

    RECRUITING

    Sydney, New South Wales, 2148, Australia

  • Royal Adelaide Hospital - Cardiology Department

    RECRUITING

    Adelaide, South Australia, 5000, Australia

  • S.C Milena Sante SRL

    RECRUITING

    Galati, 800001, Romania

  • S.C. Top Diabet Srl

    RECRUITING

    Craiova, Dolj, 200515, Romania

  • SC Nutrilife SRL

    RECRUITING

    Bucharest, 013764, Romania

  • Semmelweis Egyetem

    NOT_YET_RECRUITING

    Budapest, 1083, Hungary

  • South Broward Research LLC

    RECRUITING

    Miramar, Florida, 33027, United States

  • Specjalistyczna Praktyka Lekarska Diabetologia, Leczenie Cukrzycy i Otyłości lek. Monika Piwowar

    RECRUITING

    Kielce, 25-355, Poland

  • Spitalul Clinic Judetean De Urgenta Pius Brinzeu Timisoara

    RECRUITING

    Timișoara, 300723, Romania

  • Studiengesellschaft Dres. Könemann/Steinmann GbR

    NOT_YET_RECRUITING

    Bünde, 32257, Germany

  • Szegedi Tudomanyegyetem St Györgyi Albert Klinikai Központ

    RECRUITING

    Szeged, Csongrád-Csanád, 6725, Hungary

  • Szent Margit Rendelőintézet Nonprofit Kft.

    RECRUITING

    Budapest, 1032, Hungary

  • Tekton Research Inc

    RECRUITING

    San Antonio, Texas, 78258, United States

  • The Catholic University of Korea, Seoul ST. Mary's Hospital_Endocrinology

    NOT_YET_RECRUITING

    Seoul, 06591, South Korea

  • The Vancouver Clinic

    NOT_YET_RECRUITING

    Vancouver, Washington, 98664, United States

  • Uniwersytecki Szpital Kliniczny w Bialymstoku

    RECRUITING

    Bialystok, 15-276, Poland

  • Versdias - Diabetologikum Amberg

    RECRUITING

    Amberg, Bavaria, 92224, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.